Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03531749
Other study ID # FSSA2016051
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2017
Est. completion date May 2017

Study information

Verified date May 2018
Source Universidad Autónoma del Estado de Hidalgo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Human immunodeficiency virus (HIV) infection continues to be a pandemic, Mexico has around 184,000 people infected by this virus. A common metabolic problem for these patients is oxidative stress (OS), which has been related with the progression of the disease and the presence of comorbidities. Pomegranate is a fruit rich in antioxidants, which potentially can inhibit or reduce deleterious metabolic compounds resulting from OS; however; it has never been tested in patients infected with HIV. The present project was done in patients HIV+ from state of Hidalgo in order to see the effects of microencapsulated red pomegranate juice (MRPJ) and ascorbic acid (AA) on antioxidant activity and lipid peroxidation both biomarkers of oxidative stress. Sixty subjects were recruited, 30 HIV positive (HIV+) and 30 HIV negative (HIV-). Three subgroups (n=10) were formed from each group: 1) supplemented with (1g/d) MRPJ; 2) supplemented with 1g/d AA; and 3) control group (unsupplemented). The intervention lasted 90 days and blood samples were taken four times: at the beginning and every 30 days. Antioxidant activity in the blood serum was measured by the DPPH (2,2-diphenyl-1-picrylhydrazyl) and ABTS + (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) methods while lipid peroxidation by malondialdehyde (MDA) levels which was measured by TBARS method. The baseline results showed a significant decrease of antioxidant activity in HIV+ groups compared to the HIV- groups, although there was no significant difference in lipid peroxidation, as measured by MDA assay levels. Several studies suggest that the reduction of antioxidant activity is a consequence of the infection and the antiretroviral treatment, although the organism tries to reestablish it unbalance it usually fails, thus (OS) is significant in these patients. The groups that received AA had antioxidant activity greater than the MRPJ treated. MRPJ treatment, however, the groups that received MRPJ had significantly reduced lipid peroxidation. Reduced lipid peroxidation could have more beneficial effects on HIV+ subjects since the reduction of markers of OS, such as lipid peroxidation, has been associated with reductions in the risk of death from HIV.


Description:

Since Patients HIV+ suffer oxidative stress, microencapsulated of red pomegranate juice will be evaluated for decreasing oxidative stress in HIV+ patients it will be compared with patients treated with ascorbic acid. The supplementation will take 90 days and blood samples were taken four times: at the beginning of the study and every 30 days thereafter. Antioxidant activity in the blood serum was measured by the DPPH and ABTS+ methods lipid peroxidation was measured as stress oxidative markers


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date May 2017
Est. primary completion date May 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria:

- Over 18 years

- Having a positive HIV diagnosis

- Having antiretroviral treatment

- Status of one of the following clinical categories A1, A2, B1 and B2 at the time of the study start,

- Residents of the city of Pachuca

Exclusion Criteria:

- Subjects taking antioxidants

- Pregnant women.

- Subjects taking of angiotensin-converting enzyme inhibitors (e.g.captopril or enalapril).

- subjects who do not comply with at least 95% of the adherence of the supplementation

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
HIV+ MRPJ
supplemented with (1g/d) MRPJ
HIV+ ascorbic acid
Supplemented with (1g/d) AA

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Universidad Autónoma del Estado de Hidalgo National Council of Science and Technology, Mexico

Outcome

Type Measure Description Time frame Safety issue
Primary Biochemical analyses to determine antioxidant capacity Four different tests for antioxidant activity were utilized. Plasma antioxidant capacity, catalase, H2O2, and TBARS At 0 time (baseline)
Secondary Biochemical analyses to determine antioxidant capacity Four different tests for antioxidant activity were utilized. Plasma antioxidant capacity, catalase, H2O2, and TBARS 30 days after intervention
See also
  Status Clinical Trial Phase
Completed NCT00639145 - Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol
Completed NCT01152684 - Complementary & Alternative Medicine Use in HIV+ Latinos in the US-Mexico Border
Completed NCT01957748 - CCTG 594: Engagement and Retention in Care for HIV+ N/A
Completed NCT01818258 - IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children Phase 4
Withdrawn NCT03660722 - Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral Naïve HIV-1 Positive Subjects N/A
Completed NCT01793467 - Transplantation and the Use of Raltegravir in HIV-Infected Patients N/A
Completed NCT02938377 - Alcohol Research Consortium in HIV-Intervention Research Arm Phase 4
Completed NCT01898754 - Oligonucleotide Ligation Assay (OLA) Resistance Study N/A
Active, not recruiting NCT01365065 - Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy Phase 2
Completed NCT00106795 - Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS N/A
Not yet recruiting NCT02404233 - Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Phase 4
Completed NCT01154543 - Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes N/A
Completed NCT01154556 - RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice N/A
Completed NCT00857350 - The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment N/A
Recruiting NCT01875588 - Thinking and Memory Problems in People With HIV
Completed NCT01941121 - CCTG 593: Testing and Linkage to Care N/A
Terminated NCT01904201 - Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People N/A
Enrolling by invitation NCT00941889 - The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata N/A
Completed NCT02935296 - Integrated Treatment and Prevention for People Who Inject Drugs Phase 3
Completed NCT01536899 - Medical Marijuana Use in HIV+ Patients Prospective Cohort Study